ChromaDex Corporation logo
ChromaDex Corporation CDXC
report update icon

Quarterly report 2026-Q2
added 08-04-2026

ChromaDex Corporation Financial Statements 2025-2010 | CDXC

Annual Financial Statements ChromaDex Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

- 431 M 130 M 118 M 183 M 270 M 245 M 179 M 228 M 143 M 108 M - 164 M 56.9 M 77.2 M -

Shares

79.2 M 75.9 M 75 M 69.7 M 67.2 M 57.1 M 57.1 M 55 M 44.6 M 35.9 M 35.5 M - 33.3 M 30.1 M 16.1 M -

Historical Prices

- 5.67 1.73 1.69 2.73 13.9 3.69 3.49 5.45 2.76 4.02 4.14 5.16 2.19 1.98 -

Net Income

17.4 M 8.55 M -4.94 M -16.5 M -27.1 M -19.9 M -32.1 M -33.3 M -11.4 M -2.77 M -5.39 M - -4.42 M -11.7 M -2.05 M -

Revenue

129 M 99.6 M 83.6 M 72 M 67.4 M 59.3 M 46.3 M 31.6 M 21.2 M 22 M 15.3 M - 10.2 M 11.6 M 7.57 M -

Cost of Revenue

46.2 M 38 M 32.8 M 29.3 M 26 M 24 M 20.5 M 15.5 M 10.7 M 11.3 M 9.99 M - 7.03 M 9.34 M 5.64 M -

Gross Profit

83.2 M 61.6 M 50.8 M 42.8 M 41.5 M 35.3 M 25.8 M 16.1 M 10.5 M 8.48 M 5.33 M - 3.13 M 2.28 M 2.94 M -

Operating Income

16.3 M 7.73 M -5.6 M -18.6 M -27.1 M -19.9 M -31.3 M -33.2 M -16.4 M -2.91 M -5.23 M - -4.39 M -11.6 M -7.86 M -

Interest Expense

- - 661 K 3 K -55 K 71 K 847 K 79 K 153 K 333 K 159 K - 34.3 K 29 K -32.1 K -

EBITDA

16.9 M 8.39 M -4.73 M -17.8 M -26.2 M -18.3 M -29.8 M -32.3 M -15.7 M -1.82 M -4.97 M - -4.12 M -11.3 M -1.64 M -

Operating Expenses

66.9 M 53.9 M 56.4 M 61.4 M 68.6 M 55.1 M 57.1 M 49.2 M 26.9 M 10.6 M 10.6 M - 7.52 M 13.9 M 4.96 M -

General and Administrative Expenses

27.1 M 18.4 M 25 M 28.3 M 36.4 M 30.4 M 34.3 M 27.1 M 17.6 M 7.42 M 8.37 M - 5.11 M 13.9 M 4.96 M -

All numbers in USD currency

Quarterly Income Statement ChromaDex Corporation

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

79.3 M 79.9 M 79.8 M 79.2 M 77.8 M 77.3 M 76 M 75.6 M 75.2 M 75 M 75 M 75 M 74.8 M 74.6 M 68.3 M 68.3 M 68.3 M 68.1 M 68.2 M 68 M 64.2 M 61.9 M 61.7 M 60.9 M 59.8 M 59.6 M 57.7 M 55.5 K 55.3 K 55.1 K 55.1 K 54.9 K 54.9 K 51.2 M 47.1 K 42.1 M 38 M 37.9 M 37.9 M 37 M 36.4 M 35.6 M 107 M 35.8 M 35.7 M - 107 M 106 M 106 M 104 M 101 M 99.8 M 94.6 M 92.1 M 92.4 M 91.4 M 84.7 M 72.9 M 70.6 M 65 M 72.9 M

Net Income

963 K 6.32 M 4.58 M 3.61 M 5.06 M - 1.88 M -15 K -492 K - -959 K -2.19 M -1.9 M - -985 K -6.4 M -7.74 M - -8.86 M -5.57 M -7.38 M - -4.22 M -3.71 M -5.9 M - -7.2 M -7.76 M -8.34 M - -8.6 M -8.05 M -8.44 M -8.82 M 2.14 M -2.76 M -1.93 M -2.15 M -954 K -82.7 K 256 K -1.23 M -3.72 K -315 K -1.03 M - -660 K -1.65 M -1.85 M -724 K -1.25 M -1.02 M -1.42 M - -1.54 M -3.99 M -4.43 M - -2.4 M -1.84 M -1.16 M

Revenue

29.8 M 31.5 M 34 M 31.1 M 30.5 M - 25.6 M 22.7 M 22.2 M - 19.5 M 20.3 M 22.6 M - 17.1 M 16.7 M 17.3 M - 17.3 M 17.7 M 14.7 M - 14.2 M 15.3 M 14.3 M - 12.1 M 11.1 M 10 M - 8.12 M 7.8 M 6.57 M - 6.08 M 4.22 M - - - - - - - - - - - - - - - - - - - - - - 1.83 M 1.94 M -

Cost of Revenue

10.5 M 11.5 M 12.1 M 10.9 M 11.2 M - 9.34 M 9.05 M 8.7 M - 7.53 M 7.97 M 9.04 M - 6.86 M 6.69 M 6.73 M - 6.73 M 6.89 M 5.45 M - 5.73 M 6.2 M 6.03 M - 5.3 M 4.85 M 4.75 M - 3.76 M 3.96 M 3.43 M - 3.17 M 2.11 M 1.75 M - 2.07 M 4.7 M 3.88 M - 3.81 M 3.63 M 3.33 M - 2.62 M 2.46 M 2.09 M - 1.97 M 1.75 M 1.66 M - 2.38 M 1.91 M 2.39 M - 1.36 M 1.36 M 1.52 M

Gross Profit

19.3 M 20 M 21.9 M 20.2 M 19.3 M - 16.2 M 13.7 M 13.5 M - 12 M 12.4 M 13.5 M - 10.2 M 10 M 10.5 M - 10.6 M 10.8 M 9.23 M - 8.45 M 9.09 M 8.31 M - 6.75 M 6.25 M 5.3 M - 4.36 M 3.85 M 3.14 M 3.83 M 2.92 M 2.11 M 1.62 M 2.01 M 1.86 M 3.67 M 2.84 M 1.42 M 2.48 M 2.47 M 1.93 M - 1.52 M 1.4 M 985 K 749 K 750 K 961 K 673 K - 1.25 M 765 K -604 K - 466 K 581 K 1.02 M

Operating Income

700 K 1.58 M 4.24 M 3.18 M 4.77 M - 1.6 M -256 K -731 K - -1.15 M -2.32 M -1.97 M - -3.06 M -6.39 M -7.73 M - -8.84 M -5.55 M -7.36 M - -4.2 M -3.69 M -5.89 M - -6.89 M -7.18 M -8.37 M - -8.6 M -7.94 M -8.4 M -8.78 M -3.18 M -2.65 M -1.77 M -2.17 M -924 K 159 K 32.1 K -1.1 M 177 K -184 K -906 K - -647 K -1.64 M -1.84 M -715 K -1.24 M -1.01 M -1.42 M - -1.53 M -3.99 M -4.42 M - -2.4 M -1.83 M -1.15 M

Interest Expense

- - - - - - - - 239 K - 188 K 125 K 66 K - -5 K -10 K -8 K - 15 K 12 K 19 K - 19 K 24 K 12 K - 314 K 575 K 35 K - 9 K 48 K 44 K - 45 K 36 K 28 K - 2.26 K 145 K 188 K - 182 K 132 K 120 K - 12.4 K 12 K 9.89 K - 8.67 K 8.06 K 7.79 K - 6.86 K 7.56 K 8.26 K - 7.52 K 8.21 K 8.87 K

EBITDA

933 K 1.69 M - - 4.93 M - - - -553 K - - - -1.74 M - -2.42 M -5.97 M -7.53 M - -8.16 M -5.11 M -7.14 M - -3.54 M -3.26 M -5.68 M - -6.33 M -6.82 M -8.2 M - -8.16 M -7.67 M -8.28 M -8.78 M -2.78 M -2.39 M -1.64 M -2.17 M -690 K 318 K 115 K -1.1 M 387 K -46.8 K -839 K - -486 K -1.53 M -1.79 M -715 K -1.05 M -879 K -1.34 M - -1.28 M -3.82 M -4.34 M - -2.15 M -1.67 M -1.07 M

Operating Expenses

18.6 M 18.4 M 17.7 M 17 M 14.6 M - 14.6 M 13.9 M 14.2 M - 13.1 M 14.7 M 15.5 M - 13.3 M 16.4 M 18.3 M - 19.4 M 16.4 M 16.6 M - 12.6 M 12.8 M 14.2 M - 13.6 M 13.4 M 13.7 M - 13 M 11.8 M 11.5 M 12.6 M 6.09 M 4.76 M 3.39 M 4.18 M 2.79 M 3.51 M 2.81 M 2.52 M 2.3 M 2.65 M 2.83 M - 2.17 M 3.04 M 2.82 M 1.46 M 1.99 M 1.97 M 2.09 M - 2.79 M 4.75 M 3.82 M - 2.86 M 2.42 M 2.17 M

General and Administrative Expenses

6.97 M 7.24 M 7.13 M 7.27 M 5.18 M - 6.3 M 5.66 M 5.35 M - 5.84 M 7.3 M 6.42 M - 6.18 M 7.16 M 8.95 M - 11.2 M 9.13 M 9.55 M - 6.59 M 6.92 M 8.84 M - 7.97 M 7.93 M 8.33 M - 6.77 M 6.6 M 6.83 M - 3.95 M 2.61 M 2.32 M - 1.73 M 2.31 M 1.99 M - 1.56 M 1.84 M 2.13 M - 1.65 M 2.47 M 2.34 M - 1.45 M 1.34 M 1.36 M - 1.98 M 2.88 M 1.96 M - 2.21 M 1.85 M 1.72 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ChromaDex Corporation CDXC
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ChromaDex Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.6 5.56 % $ 6.41 B israelIsrael
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 64.67 0.11 % $ 12.4 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.85 0.12 % $ 319 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.78 1.13 % $ 3.03 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 34.07 0.17 % $ 382 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 5.6 2.06 % $ 3.74 M usaUSA
Codexis Codexis
CDXS
$ 1.59 0.3 % $ 139 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.1 1.25 % $ 303 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 199.02 0.31 % $ 9.9 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.28 0.1 % $ 1.62 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aytu BioScience Aytu BioScience
AYTU
$ 2.25 0.45 % $ 14.1 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada